ATG16L1

Across TCGA pan-cancer cohorts, ATG16L1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG16L1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATG16L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATG16L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where ATG16L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.233	0.920	.001	32	view →
CCRCC	DFS	Tertile	IV	1.000	0.162	.024	19	view →
PDAC	OS	Tertile	II,III,IV	0.672	0.359	.009	15	view →
COAD	DFS	Median	III,IV	1.000	0.895	.038	12	view →
GBM	DFS	Median	All	0.204	0.319	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG16L1–LUAD (OS)

Open the LUAD breakdown →